switching from Test E to Test P

John1985

John1985

Work Hard-Play Hard
has anybody ever switched from Test E to Test P in the middle of the cycle? I've been on Test E 500wk ..this is my 4th week and I'm thinking about doing Test P for the next 4 weeks?

bad move ? or it doesn't matter?
 
John1985 said:
has anybody ever switched from Test E to Test P in the middle of the cycle? I've been on Test E 500wk ..this is my 4th week and I'm thinking about doing Test P for the next 4 weeks?

bad move ? or it doesn't matter?
Click to expand...

It's ok, but why in the 4th week? The test e would just be starting to work it's magic. But if it's because that's all u have it's no problem, will just need more frequent injections (EOD) rather than twice per week
 
John1985 said:
has anybody ever switched from Test E to Test P in the middle of the cycle? I've been on Test E 500wk ..this is my 4th week and I'm thinking about doing Test P for the next 4 weeks?

bad move ? or it doesn't matter?
Click to expand...

If you could avoid it I'd try not to do it.

As China mentioned the test E will be hitting hard soon and if you figure in the kick in time for prop than it's really not much of a "cycle".
 
I like to finish all of my cycles with prop. It helps me start pct earlier and I feel it helps me bounce back quicker. I would def run the test e at least 5 more weeks before finishing up ur cycle with prop. (if you choose to do that) Like Dre and China mentioned.... I wouldnt stop the test e right when it is kicking in after 5 weeks.
 
Thanks guyss, so y "resource" said I need to get on the Test P to cut down some of the bf, is that true ? and that was the only reason I was considering it.

Just if anybody was wondering..I'm around 18bf right now and trying to get down to 10bf and I'm follwing 3J's diet.
 
what if I add Anavar to my current cycle instead of switching to test P? Will anavar help me with bodyfat?
 
DreDay187 said:
Anavar will help with sub q body fat near and around the stomach but not to a significant degree really
Click to expand...

How can var or any substance contribute to localized fat loss?? There are way too many variables in fat loss per individual to generalize like that bro. The first place someone gains fat is by and large the last place they will lose it.

Any substance out there that contributes to fat loss will not decrease more in any one location as fat is pretty much evenly distributed throughout the body

OP... If u want something to reduce fat consider t3 or t3/clen, var is NOT the answer ;)
 
China_Wall said:
How can var or any substance contribute to localized fat loss?? There are way too many variables in fat loss per individual to generalize like that bro. The first place someone gains fat is by and large the last place they will lose it.

Any substance out there that contributes to fat loss will not decrease more in any one location as fat is pretty much evenly distributed throughout the body

OP... If u want something to reduce fat consider t3 or t3/clen, var is NOT the answer ;)
Click to expand...

It has to do with the androgen receptors in the stomach and their activation/transcription by anavar.

J Clin Endocrinol Metab. 2004 Oct;89(10):4863-72.
Effects of androgen therapy on adipose tissue and metabolism in older men.
Schroeder ET1, Zheng L, Ong MD, Martinez C, Flores C, Stewart Y, Azen C, Sattler FR.
Author information

Abstract
We investigated the effects of oxandrolone on regional fat compartments and markers of metabolism. Thirty-two 60- to 87-yr-old men (body mass index, 28.1 +/- 3.4 kg/m(2)) were randomized to oxandrolone (20 mg/d; n = 20) or matching placebo (n = 12) treatment for 12 wk. Oxandrolone reduced total (-1.8 +/- 1.0 kg; P < 0.001), trunk (-1.2 +/- 0.6 kg; P < 0.001), and appendicular (-0.6 +/- 0.6 kg; P < 0.001) fat, as determined by dual energy x-ray absorptiometry. The changes in total and trunk fat were greater (P < 0.001) than the changes with placebo. By magnetic resonance imaging, visceral adipose tissue decreased (-20.9 +/- 12 cm(2); P < 0.001), abdominal sc adipose tissue (SAT) declined (-10.7 +/- 12.1 cm(2); P = 0.043), the ratio VAT/SAT declined from 0.57 +/- 0.23 to 0.49 +/- 0.19 (P = 0.002), and proximal and distal thigh SC fat declined [-8.3 +/- 6.7 cm(2) (P < 0.001) and -2.2 +/- 3.0 kg (P = 0.004), respectively]. Changes in proximal and distal thigh SC fat with oxandrolone were different than with placebo (P = 0.018 and P = 0.059). A marker of insulin sensitivity (quantitative insulin sensitivity check index) improved with oxandrolone by 0.0041 +/- 0.0071 (P = 0.018) at study wk 12. Changes in total fat, abdominal SAT, and proximal extremity SC fat were correlated with changes in fasting insulin from baseline to study wk 12 (r >or= 0.45; P < 0.05). Losses of total fat and SAT were greater in men with baseline testosterone of 10.4 nmol/liter or less (<or= 300 ng/dl) than in those with higher levels [-2.5 +/- 1.1 vs. -1.5 +/- 0.8 kg (P = 0.036) and -24.1 +/- 14.3 vs. -2.9 +/- 21.3 cm(2) (P = 0.03), respectively]. Twelve weeks after discontinuing oxandrolone, 83% of the reductions in total, trunk, and extremity fat by dual energy x-ray absorptiometry scanning were sustained (P < 0.02). Androgen therapy, therefore, produced significant and durable reductions in regional abdominal and peripheral adipose tissue that were associated with improvements in estimates of insulin sensitivity. However, high-density lipoprotein cholesterol decreased by -0.49 +/- 0.21 mmol/liter and directly measured low-density lipoprotein cholesterol increased by 0.57 +/- 0.67 mmol/liter and non-high-density lipoprotein cholesterol increased by 0.54 +/- 0.97 mmol/liter (P < 0.03 for each) during treatment with oxandrolone; these changes were largely reversible. Thus, therapy with an androgen that does not adversely affect lipids may be beneficial for some components of the metabolic syndrome in overweight older men with low testosterone levels.
PMID: 15472177
Click to expand...

1: Int J Obes Relat Metab Disord 1995 Sep;19(9):614-24 Related Articles, Books, LinkOut


Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men.

Lovejoy JC, Bray GA, Greeson CS, Klemperer M, Morris J, Partington C, Tulley R.

Pennington Biomedical Research Center, Baton Rouge, Louisiana 70808-4124, USA.

OBJECTIVE: To compare the effects of testosterone enanthate (TE), anabolic steroid (AS) or placebo (PL) on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means. DESIGN: Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Due to adverse blood lipid changes, the AS group was switched from oral oxandrolone (ASOX) to parenteral nandrolone decaoate (ASND) after the 3 month assessment point. SUBJECTS: Thirty healthy, obese men, aged 40-60 years, with serum testosterone (T) levels in the low-normal range (2-5 ng/mL). MAIN OUTCOME MEASURES: Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry (DEXA), insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters. RESULTS: After 3 months, there was a significantly greater decrease in subcutaneous (SQ) abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups. There were significant main effects of treatment at 3 months on serum T and free T (increased in the TE group and decreased in the ASOX group) and on thyroid hormone parameters (T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups). There was a significant decrease in HDL-C, and increase in LDL-C in the ASOX group, which led to their being switched to the parenteral nandrolone decanoate (ASND) after 3 months. ASND had opposite effects on visceral fat from ASOX, producing a significant increase from 3 to 9 months while continuing to decrease SQ abdominal fat. ASND treatment also decreased thigh muscle area, while ASOX treatment increased high muscle. ASND reversed the effects of ASOX on lipoproteins and thyroid hormones. The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters. CONCLUSIONS: Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat. TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat.
Click to expand...
 
I'd stay on E until the end like someone said up there. I don't like E because I puff up like a bull frog, and it's so noticeable. I've always favored sust, it's easy for me to regulate water retention, I feel better on it, and it's an easy switch to prop when I decide to cut. I don't ever come off though either, I just switch my shit up and take cruise breaks.
 
I'd personally stick with the e, but that's because I'm biased and can't get enough of e. Never really liked p too much, but thats just me. Do what you think is right.
 
You must log in or register to reply here.

Similar threads

casanovaaa
Back on the Sauce: First Cycle in 5 Years – Thoughts & Plans
Replies
4
Views
1K
giankenbellfore
G
R
Test / Deca Cycle - Need Advice
Replies
1
Views
1K
hammer2204
hammer2204
J
Need advice on dosage and cycle length
Replies
1
Views
1K
bigandgrowing
B
C
48 year old male on TRT adding a supraphysiologic cycle w/ some "PCT"
Replies
0
Views
880
cheroxy
C
S
Sust + Dzine cycle critique
Replies
0
Views
1K
spirall08
S
Back
Top